Akihiro Hirakawa

5PUBLICATIONS
7CO-AUTHORS
Haematological tumoursPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Basic pharmacologyCancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Oct 30, 2026
Leveraging non-concurrent controls for time-to-event endpoints in platform trials for infectious diseases.

|May 10, 2026
Evolving Variants, Shifting Outcomes: Implications for Nonconcurrent Controls in Platform Trials for COVID-19.

|Mar 10, 2025
BF-BOIN-ET: A Backfill Bayesian Optimal Interval Design Using Efficacy and Toxicity Outcomes for Dose Optimization.

Kentaro Takeda, Jing Zhu, Akihiro Hirakawa

|Jan 07, 2022
Regulatory issues and the potential use of Bayesian approaches for early drug approval systems in Japan.

Akihiro Hirakawa, Hiroyuki Sato, Masataka Igeta

|Aug 12, 2020
A Bayesian basket trial design accounting for uncertainties of homogeneity and heterogeneity of treatment effect among subpopulations.

Junichi Asano, Akihiro Hirakawa

Pageof 1

Frequent Collaborators

2 joint publications

Shin Watanabe

2 joint publications

Hiroyuki Sato

1 joint publications

Masataka Igeta

1 joint publications

Satoshi Teramukai